Myelodysplastic Syndromes (MDS)
STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes
Acute myeloid leukemia Acute myeloid leukemia: (uh-KYOOT my-uh-LOYD loo-KEE-mee-uh) A cancer of the blood cells.
Genome sequencing in the management of myelodysplastic syndromes and related disorders
Myeloid neoplasms originate from the clonal proliferation of hematopoietic stem cells stem cells: Cells in the body that develop into other cells. There are two main sources of stem cells.
Diagnosis of myelodysplastic syndromes: the classic and the novel
The myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the
Treatment of high-risk myelodysplastic syndromes
Myelodysplastic syndrome (MDS) is considered to be a heterogeneous myeloid malignancy with a common origin in the hematopoietic stem cell compartment and is generally divided into lower- and higher-risk forms. While the treatment goals for lower-risk MDS are to decrease transfusion requirements and transformation into acute leukemia, the major aims for higher-risk MDS are to prolong survival and ultimately cure the patient.
Treatment of lower-risk myelodysplastic syndromes
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone
Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT
Original Publication Date
Article Source
External Web Content
For patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capable of eradicating disease-related mutant hematopoietic cells and establishing normal donor hematopoiesis…
How is transfusion dependence evolving in anemia treatment in MDS?
Original Publication Date
Article Source
External Web Content
A roundtable discussion on anemia management in myelodysplastic syndromes. Featuring moderator Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center; Amy DeZern, MD, MHS, Johns Hopkins Medicine; Tiffany Tanaka, MD, of the University of California San…
Jane Biehl: Moving Slower and Slower After Myelodysplastic Syndrome
Original Publication Date
Article Source
External Web Content
I have honestly been frustrated lately. I am slowing down increasingly, and it has even become noticeable to others. I wrote an article in November about how nice it was to slow down and smell the roses. But now it seems like too much. In my previous life (before cancer), I moved…
What are some of the new therapies discussed at ASH 2024?
Original Publication Date
Article Source
External Web Content
A roundtable discussion on anemia management in myelodysplastic syndromes featuring moderator Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center; Amy DeZern, MD, MHS, Johns Hopkins Medicine; Tiffany Tanaka, MD, of the University of California San…